乳腺浸润性导管癌中TopoⅡ和GST-π表达及意义  

Expression and significance of TopoⅡ and GST-πin breast invasive ductal carcinoma

作　　者：胡云[1] 王汉晋[1] 周萍[1] 朱春花[1] 

机构地区：[1]南京医科大学附属南京医院普通外科,江苏省210012

出　　处：《江苏医药》2013年第21期2549-2551,2508,共3页Jiangsu Medical Journal

基　　金：南京医科大学科技发展基金重点项目(08NMUZ038)

摘　　要：目的探讨耐药蛋白DNA拓扑异构酶Ⅱ(TopoⅡ)和谷胱甘肽-S-转移酶-π(GST-π)与乳腺浸润性导管癌的临床病理特征及分子分型的关系。方法原发性乳腺浸润性导管癌患者125例,应用免疫组化SP法检测TopoⅡ和GST-π的表达。结果 TopoⅡ和GST-π阳性表达率分别为75.2%和44.8%。TopoⅡ的阳性表达在Luminal-B型和人表皮生长因子受体2(Her-2)过表达型的阳性率高于Luminal-A型(90.9%和87.5%vs.60.7%)(P<0.05);TopoⅡ表达率随着肿瘤组织学分级的增加而升高(P<0.05)。GST-π的表达在年龄、肿瘤大小、淋巴结转移、组织学分级、分子分型以及临床分期中均无明显差异。结论在浸润性导管癌中,TopoⅡ与肿瘤的恶性程度及Her-2基因的过表达有关。Objective To explore the expression and significance of DNA topoisomerase Ⅱ （Topo Ⅱ ） and glutathione-S-tranferase-π（GST-π） in breast invasive ductal carcinoma. Methods With immunohistochemistry, the expressions of Topo Ⅱ and GST-π were detected in 125 cases with primary invasive ductal carcinoma. Results The positive rates of Topo Ⅱ and GST-n were 75.20% and 44. 80%, respectively. The positive expression of Topo Ⅱ in Luminal-B and Her-2-overexpression were higher than that in luminal-A（90.9% and 87.5% vs. 60. 7%） （P〈0. 05）. Topo Ⅱ expression was higher in the carcinoma with higher histological grade than that in those with lower histological grade（P〈0. 05）. The positive expression of GST-π was not significantly related to the age, tumor diameter, lymph node metastasis, histological grade, molecular type and clinical stage. Conclusion Topo Ⅱ is significantly correlated with the malignancy and HER-2-overexpression in breast invasive ductal carcinoma.

关 键 词：乳腺癌 DNA拓扑异构酶Ⅱ 谷胱甘肽-S-转移酶-Π 

分 类 号：R737[医药卫生—肿瘤]